Ajax Health Secures $85M to Accelerate Medical Device Innovations

The company identifies areas of under-served medical need and matches human and financial capital to advance the technologies.

Photos have been modified. Courtesy of Sterling Medical Devices.

Ajax Health II today announced that it has raised more than $85 million to strategically operate and expand innovative medical device companies.

Funding was led by HealthQuest Capital, a growth equity firm that recently closed a $440 million fund to invest in health technology companies, with additional investments from Aisling Capital and Polaris Partners.

Ajax Health aims to accelerate medical innovations by identifying opportunities and participating in building innovative medical device companies that could improve lives and bring speed, simplicity and cost-efficiency to healthcare.

The company, founded in 2017 by Duke Rohlen, CEO, will look for disruptive technologies in the medical device space and value-creating business models that have the potential for high-exit demand where returns can be realized within four years. Ajax is seeking leaders at companies with a strategic combination of market, technical and execution experience.

Then, the team will integrate their expertise and experience to support the medical device companies.

“Ajax Health approaches medical device innovation in a novel way, applying best-in-class strategies to pinpoint technologies with the greatest opportunity to take off, then rapidly developing them into a fully integrated business,” said Garheng Kong, M.D., Ph.D., founder and managing partner of HealthQuest.

Get the best insights in healthcare analytics directly to your inbox.


Health Tech Kicks Off 2019 with $119M in Funding

5 Emerging Technologies that Will Change Healthcare

At $8B, Annual Digital Health Funding Has Already Surpassed 2017

Related Videos
Jim Adams, AllianceRx Walgreens Prime
Heather Bonome, Pharm.D., URAC
George Van Antwerp, MBA
Jesse Fasolo
Edmondo Robinson, MD, MBA
Edmondo Robinson, MD
Related Content
© 2023 MJH Life Sciences

All rights reserved.